Chemistry:Cendifensine

From HandWiki

Cendifensine (INN) is a monoamine reuptake inhibitor (MRI)[1] related to the amphetamines and cathinones which has not been marketed at this time.[2][3][4] It was first described by 2013[4] and its INN was proposed in 2024.[2] The drug has been patented by Noema Pharma, which is developing a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) known as NOE-115 for the treatment of vasomotor symptoms as well as for binge-eating disorder and depressive disorders.[5][6][7]

See also

References

  1. Garibaldi G, "Triple uptake inhibitor for the treatment of atypical depression", WO patent 2023/161533A1, published 31 August 2023
  2. 2.0 2.1 "Proposed INN: List 132 International Nonproprietary Names for Pharmaceutical Substances (INN)". WHO Drug Information 38 (4). 2024. https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf. "cendifensinum cendifensine (3,4-dichlorophenyl)[(3S)-3-propylpyrrolidin-3-yl]methanone monoamine reuptake inhibitor [...] C14H17Cl2NO 1034048-49-1". 
  3. "(3,4-Dichlorophenyl)[(3S)-3-propyl-3-pyrrolidinylmethanone"]. Global Substance Registration System (GSRS). National Center for Advancing Translational Sciences (NCATS), U.S. National Institutes of Health. https://frontend.m.jchem.test.gsrs.ncats.io/ginas/app/ui/substances/a4e246fe-8898-47dd-bd50-7942a95ee893. 
  4. 4.0 4.1 Adam JM, Dvorak CA, Fishlock D, Humphreys ER, Iding H, Pfleger C, Rege PD, Shi X, Vitale J, Wang S, Zajac M, "(3,4-dichloro-phenyl)-((s)-3-propyl-pyrrolidin-3-yl)-methanone hydrochloride and manufacturing processes", CA patent 2860810A1, published 23 April 2013
  5. "NOE 115". 21 May 2024. https://adisinsight.springer.com/drugs/800061339. 
  6. "Delving into the Latest Updates on Noema Pharma AG with Synapse". 23 January 2025. https://synapse.patsnap.com/organization/70b6acd384a69a3be45e4e9aa30ce838#pipeline. 
  7. "Noema Pharma". 18 June 2021. https://noemapharma.com/pipeline/.